Results 71 to 80 of about 50,656 (201)

Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes

Journal of Diabetes Investigation
Aims To evaluate characteristics and glycemic outcomes in individuals with type 2 diabetes using injectable therapies in real‐world clinical practice in Tianjin, China.
Qiumei Zhang, Yaqing Fan, Xixi Liu, Minlu Zhang, Jiewen Zhang, Qin Du, Lei Kang, Liming Chen   +7 more
doaj   +1 more source

Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection

Frontiers in Medicine
Endothelial dysfunction represents the critical pathophysiological mediator linking the modern epidemics of obesity, type 2 diabetes mellitus, and cardiovascular disease.
Allegra Battistoni, Linda Piras, Nicola Tartaglia, Francesco Maria Carrano, Claudia De Vitis, Emanuele Barbato   +5 more
doaj   +1 more source

Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. [PDF]

, 2014
Background: Rodents are incapable of emesis and consequently the emetic potential of glucagon-like peptide-1 receptor (GLP-1R) agonists in studies designed to assess a potential blood glucose lowering action of the compound was missed.
A Amato, A Flint, A Rotondo, A Vella, A Wettergren, AD Farmer, AH Barnett, AM Holmes, B Kreymann, BD Kiernan, BP Bullock, C Tourrel, CA Richards, Chi-Kong Yeung, CM Edwards, CR Abbott, David TW Yew, DD De Leon, Ge Lin, GJ Sanger, GM Holmes, GR Morrow, I Billig, I Doweck, INC Lawes, J Kim, JA Kim, JL Iltz, JL Lachey, JM Egan, John A Rudd, JP Gutzwiller, JP Gutzwiller, JP Gutzwiller, K Venkova, KE Mayo, KP Kinzig, L Van Bloemendaal, L Zheng, LL Baggio, LT LaCount, M Reardon, MM Combettes, N Imeryuz, N Percie Du Sert, N Percie du Sert, N Percie Du Sert, NA Gupta, Nathalie Percie Du Sert, NH Greig, P Bhandari, Paul LR Andrews, PJ Gianaros, PJ Shughrue, PL Andrews, R Goke, R Goke, R Shirazi, RM Stern, S Madsbad, SE Ayachi, SE Kanoski, SW Chan, SW Chan, SW Chan, Sze Wa Chan, T Perry, T Tolessa, T Tolessa, V Bucinskaite, Y Wei, Zengbing Lu   +71 more
core   +1 more source

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Nature Communications
Glucagon-like peptide-1 receptor agonists act via appetite suppression and caloric restriction. These treatments can result in significant muscle loss, likely due to evolutionary mechanisms protecting against food scarcity as muscle is a major energy ...
Jason W. Mastaitis, Daniel Gomez, José G. Raya, Diana Li, Soo Min, Michael Stec, Sandra Kleiner, Toya McWilliams, Judith Y. Altarejos, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman   +11 more
doaj   +1 more source

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine [PDF]

, 2019
Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control, it is often necessary to rely on combination therapy of multiple drugs or insulin because uncontrolled ...
Andreozzi, F, Mannino, Gc, Sesti, G
core   +1 more source

A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs [PDF]

, 2017
Background: Diabetes mellitus is a metabolic disorder defined by high blood glucose. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are a newer class of medications that offer potential 2 to 3 kg weight loss and a 1% to 1.5% decrease in A1c.
Beutel Darrow, Shelby L.
core   +1 more source

GLP-1 Agonists in Type 1 Diabetes Mellitus: A Review of the Literature [PDF]

, 2016
Objective: To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus (T1DM). Data Sources: A search using the MEDLINE database, EMBASE, and Cochrane Database was performed through March 2016 using the search terms glucagon-like ...
Janzen, Kristin M., Nisly, Sarah A., Steuber, Taylor D.   +2 more
core   +2 more sources

Euglycemic Ketoacidosis After the Addition of Glucagon-Like Peptide-1 Receptor Agonist: A Case Report

Annals of Internal Medicine: Clinical Cases
Euglycemic diabetic ketoacidosis (euDKA) is an acute, life-threatening metabolic emergency. It has been associated with several factors, including sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Ernest Oji Kanu, Daniel K. Kim, Rejeesh Menon, Carissa Burke, Nathan Vicknair   +4 more
doaj   +1 more source

Review article: a comparison of glucagon-like peptides 1 and 2. [PDF]

, 2013
BACKGROUND: Recent advancements in understanding the roles and functions of glucagon-like peptide 1 (GLP-1) and 2 (GLP-2) have provided a basis for targeting these peptides in therapeutic strategies.
Amato, Amato, Amato, Amin, Andrews, Andrews, Angelone, Anini, Anvari, Au, Baggio, Baggio, Bahrami, Baldassano, Baldassano, Bengi, Benjamin, Bjerknes, Blomgren, Booth, Bose, Boushey, Boushey, Bremholm, Brubaker, Brubaker, Brubaker, Brubaker, Buchman, Bucinskaite, Bullock, Buse, Caddy, Cameron, Cameron, Campos, Cani, Chance, Cheeseman, Cinci, Cummings, Daniel, Deacon, Deacon, Delgado-Aros, Drucker, Drucker, Drucker, Drucker, Drucker, Drucker, Drucker, Drucker, Dube, Dube, Dube, Dunphy, Estall, Farilla, Fehmann, Flint, Garber, Giralt, Goke, Guan, Guan, Gutzwiller, Gutzwiller, Hadjiyanni, Hansen, Hansen, Hargrove, Hartmann, Herrmann, Holst, Holst, Hornby, Hsieh, Hui, Iakoubov, Imeryuz, Iwai, Jeppesen, Jeppesen, Jeppesen, Jeppesen, Jeppesen, Johansen, Kato, Kendall, Kieffer, Kim, Kim, Knauf, Knudsen, Koehler, Koehler, Koopmann, Koopmann, Kunkel, Leen, Li, Lim, Linnebjerg, Liu, Liu, Lovshin, Lovshin, Lovshin, Madsbad, Marre, Martin, Martin, McDonagh, Meier, Meier, Miki, Moretto, Munroe, Nagell, Nakagawa, Naslund, Naslund, Nauck, Nelson, Nelson, Nielsen, Nikolaidis, Nystrom, Orskov, Orskov, Orskov, Orskov, Orskov, Orskov, Parks, Peters, Petersen, Petersen, Petersen, Pinelli, Portha, Reimann, Reimann, Roberge, Rocca, Rotondo, Rouille, Rowland, Rowland, Ruiz-Grande, Schirra, Schmidt, Schmidt, Schwartz, Scott, Shin, Sigalet, Sigalet, Sinclair, Skarbaliene, Sorensen, Stephens, Sturis, Tanaka, Tang-Christensen, Tang-Christensen, Tavares, Tee, Thong, Thulesen, Thulesen, Tolessa, Tolessa, Tornehave, Trivedi, Tsai, Tsai, Ugleholdt, Velazquez, Velazquez, Verdich, Voss, Vrang, Wallis, Wallis, Washizawa, Wettergren, Wettergren, Wheeler, Wideman, Wishart, Wojdemann, Wojdemann, Xiao, Xiao, Xu, Yamamoto, Yamazaki, Yusta, Yusta, Zhu, Zinman   +202 more
core   +1 more source

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists

Diabetes Care, 2011
Targeting the incretin system has become an important therapeutic approach for treating type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors. Clinical data have revealed that these therapies improve glycemic control while reducing body weight (GLP-1 receptor
openaire   +1 more source